REMS Targeting Off-Label Use Helps Aegerion’s Lomitapide Clear FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee votes 13-2 that Aegerion’s lomitapide should be approved for homozygous familial hypercholesterolemia despite serious hepatic and other risks as long as every effort is made to prevent off-label use.
You may also be interested in...
Panel Review Of Aegerion’s Lomitapide May Lead To Evolution Of Cholesterol Drug Approval Standards
FDA will be using an upcoming advisory panel review of Aegerion Pharmaceuticals Inc.’s lomitapide to see if there is still support for traditional lipid endpoints in clinical trials of cholesterol drugs.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.